Combination product comprising melagatran and dexamethasone

Details Combination product comprising melagatran and dexamethasone Combination product comprising melagatran and dexamethasone

2002-10-24

2008-11-11

Kam, Chih-Min (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S020800, C514S247000, C424S009100, C544S238000, C544S239000, C544S240000, C560S034000, C560S035000, C560S168000, C560S169000, C562S439000, C562S560000

Reexamination Certificate

active

07449446

ABSTRACT:
There is provided a combination product comprising; (A) melagatran or a pharmaceutically acceptable derivative thereof; and (B) dexamethasone or a pharmaceutically acceptable derivative there of, wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, as well as the use of such a combination product in the treatment of conditions including disseminated intravascular coagulation.

REFERENCES:
patent: 3461208 (1969-08-01), Winter
patent: 6683054 (2004-01-01), Kirk
patent: WO-94/29336 (1994-12-01), None
patent: WO-97/23499 (1997-07-01), None
patent: WO 00/64470 (2000-04-01), None
patent: WO-00/41716 (2000-07-01), None
patent: WO-01/95931 (2001-12-01), None
patent: WO-01/95932 (2001-12-01), None
Yi et al., Inflammation vol. 20, No. 2 , 165-175 (1996).
Bernard et al., “Efficacy and Safety of Recombinant Human Activated Protein C. For Severe Sepsis,” The New England Journal of Medicine 344(10):699-709 (2001).
Saito et al., “Recombinant Hirudin for the Treatment of Disseminated Intravascular Coagulation in Patients with Haematological Malignancy,” Blood Coagulation and Fibrinolysis 6:60-64 (1995).
Yamazaki et al., “Prednisolone Inhibits Endotoxin-Induced Disseminated Intravascular Coagulation and Improves Mortality in Rats: Importance of Inflammatory Cytokine Suppression,” Blood Coagulation and Fibrinolysis 10:321-330 (1999).
Eisele, B., et al., “Clinical Experience with Antithrombin III Concentrates in Critially Ill Patients with Sepsis and Multiple Organ Failure,” Sem. Thromb. Hemost., 24, 71-80 (1998).
Riewals, M., et al., “Treatment Options for Clinically Recognized Disseminated Intravascular Coagulation,” Sem. Thromb. Hemost., 24, 53-59 (1998).
Diaz-Cremades, J.M., et al., “Use of antithrombin III in critcal patients,” Intensive Care Med., 20, 577-580 (1994).
Eriksson, M., et al., “Melagatran, a Low Molecular Weight Thrombin Inhibitor, Counteracts Endotoxin-induced Haemodynamic and Renal Dysfunctions in the Pig,” Thromb. Haemost., 80-1022-1026 (1998).
Erikkson, M., et al., “Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs,” Acta Anaesthesiol. Scand., 44, 24-31 (2000).
Basu, S., et al., “Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock,” Exp. Opin. Invest. Drugs, 9(5), 1129-1137 (2000).
Martindale—The Complete Drug Reference, 32nd Edition, K. Parfitt (ed.), Pharmaceutical Press, London (1999), 1037-1039.
“Melagatran and Ximelagatran, Anticoagulant Thrombin Inhibitor,” Drugs of the Future, 26(12), 1155-1170 (2001).
Margareta, E., et al., “A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats,” Abstract—Blood, http://www.bloodjournal.org, vol. 98(11), p. 47a, (Nov. 2001).
Liu, Y.Y., “Comparison between the therapeutic effects of ginseng-aconitum-bupleurum injection and dexamethasone on septic shock complicated with disseminated intravascular coagulation induced byE. coliin dogs,” Chung Hsi I Chieh Ho Tsa Chih Chinese Journal of Modern Developments in Traditional Medicine, 10(11), 675-6, 645 (1990), STN International, File: Medline, accession No. 91098744.
coagulation induced by E. coil in dogs, Chung Hsi I Chieh Ho Tsa Chih Chinese Journal of Modern Developments in Traditional Medicine, 10(11), 675-6, 645 (1990), STN International, File: Medline, accession no. 91098744.

Affiliated with

Also associated with

Rating

Combination product comprising melagatran and dexamethasone does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination product comprising melagatran and dexamethasone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination product comprising melagatran and dexamethasone will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4036356